Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Sublingual NSV0001 in Healthy Male Volunteers
NCT02955030Phase 1Completed
- Sponsor
- Nitto
- Start
- Oct 2016
- Primary completion
- Mar 2017
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of NSV0001 in influenza (5 arms), sponsored by Nitto. Primary endpoint: Number of subjects with local and systemic reactions and subjects reporting one or more adverse events at 28 days. Started Oct 2016; status: completed.
02
Drugs
NSV0001
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02955030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955030.